nach oben

Erschienen in:

07.10.2020

The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review

verfasst von: Fatemeh Jafari, Afsane Maddah Safaei, Leila Hosseini, Sanaz Asadian, Tara Molanaie Kamangar, Fatemeh Zadehbagheri, Nahid Rezaeian

Erschienen in: Heart Failure Reviews | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

The use of chemotherapy medicines for breast cancer (BC) has been associated with an increased risk of cardiotoxicity. In recent years, there have been growing interests regarding the application of cardiovascular magnetic resonance (CMR) imaging, a safe and noninvasive modality, with the potential to identify subtle morphological and functional changes in the myocardium. In this investigation, we aimed to review the performance of various CMR methods in diagnosing cardiotoxicity in BC, induced by chemotherapy or radiotherapy. For this purpose, we reviewed the literature available in PubMed, MEDLINE, Cochrane, Google Scholar, and Scopus databases. Our literature review showed that CMR is a valuable modality for identifying and predicting subclinical cardiotoxicity induced by chemotherapy. The novel T1, T2, and extracellular volume mapping techniques may provide critical information about cardiotoxicity, in addition to other CMR features such as functional and structural changes. However, further research is needed to verify the exact role of these methods in identifying cardiotoxicity and patient management. Since multiple studies have reported the improvement of left ventricular performance following the termination of chemotherapy regimens, CMR remains an essential imaging tool for the prediction of cardiotoxicity and, consequently, decreases the mortality rate of BC due to heart failure.

Carreras G, Lachi A, Boffi R et al (2020) Burden of disease from breast cancer attributable to smoking and second-hand smoke exposure in Europe. Int J Cancer:ijc.33021. https://doi.org/10.1002/ijc.33021

Anderson WF, Jatoi I, Devesa SS (2005) Distinct breast cancer incidence and prognostic patterns in the NCI’s SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127–137. https://doi.org/10.1007/s10549-004-3777-3CrossRefPubMed

Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23:2162–2171. https://doi.org/10.1200/JCO.2005.01.014CrossRefPubMed

Cai F, Luis MAF, Lin X et al (2019) Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: preventive strategies and treatment. Mol Clin Oncol 11:15–23PubMedPubMedCentral

Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60:2504–2512. https://doi.org/10.1016/j.jacc.2012.07.068CrossRefPubMed

Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077–1084. https://doi.org/10.1056/NEJM200004133421502CrossRefPubMed

Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH (2013) Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy a systematic review. Circ Cardiovasc Imaging 6:1080–1091CrossRefPubMed

Narayan V, Ky B (2018) Common cardiovascular complications of cancer therapy: epidemiology, risk prediction, and prevention. Annu Rev Med 69:97–111. https://doi.org/10.1146/annurev-med-041316-090622CrossRefPubMedPubMedCentral

Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802286/. Accessed 1 Aug 2020

10.

Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, Douglas PS, Bhatia S, Chao C (2016) Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 34:1122–1130. https://doi.org/10.1200/JCO.2015.64.0409CrossRefPubMedPubMedCentral

11.

Moslehi JJ (2016) Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375:1457–1467CrossRefPubMed

12.

Cardiovascular toxicity of the first line cancer chemotherapeutic agents: doxorubicin cyclophosphamide, streptozotocin and bevacizumab | Request PDF. https://www.researchgate.net/publication/6639516_Cardiovascular_toxicity_of_the_first_line_cancer_chemotherapeutic_agents_Doxorubicin_cyclophosphamide_streptozotocin_and_bevacizumab. Accessed 1 Aug 2020

13.

Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH (2017) Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 1. J Am Coll Cardiol 70:2536–2551CrossRefPubMedPubMedCentral

14.

Jolly MP, Jordan JH, Meléndez GC, McNeal GR, D’Agostino RB Jr, Hundley WG (2017) Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy. J Cardiovasc Magn Reson 19. https://doi.org/10.1186/s12968-017-0373-3

15.

Pituskin E, Haykowsky M, Mackey JR et al (2011) Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 11. https://doi.org/10.1186/1471-2407-11-318

16.

Fanous I, Dillon P (2016) Cancer treatment-related cardiac toxicity: prevention, assessment and management. Med Oncol 33

17.

Jerusalem G, Moonen M, Freres P, Lancellotti P (2015) The European Association of Cardiovascular Imaging/Heart Failure Association Cardiac Oncology Toxicity Registry: long-term benefits for breast cancer treatment. Future Oncol 11:2791–2794. https://doi.org/10.2217/fon.15.227CrossRefPubMed

18.

Depardon E, Kanoun S, Humbert O, Bertaut A, Riedinger JM, Tal I, Vrigneaud JM, Lasserre M, Toubeau M, Berriolo-Riedinger A, Dygai-Cochet I, Fumoleau P, Brunotte F, Cochet A (2018) FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: comparison of EORTC criteria and PERCIST. PLoS One 13:e0199529. https://doi.org/10.1371/journal.pone.0199529CrossRefPubMedPubMedCentral

19.

Parker J, Gebretsadik T, Sabogal F, Newman J, Lawson HW (1998) Mammography screening among California Medicare beneficiaries: 1993- 1994. Am J Prev Med 15:198–205. https://doi.org/10.1016/S0749-3797(98)00045-2CrossRefPubMed

20.

Martel S, Maurer C, Lambertini M, Pondé N, de Azambuja E (2017) Breast cancer treatment-induced cardiotoxicity. Expert Opin Drug Saf 16:1021–1038CrossRefPubMed

21.

Yoon HJ, Kim HN, Yun Y et al (2015) Background intestinal 18F-FDG uptake is related to serum lipid profile and obesity in breast cancer patients. PLoS One 10. https://doi.org/10.1371/journal.pone.0141473

22.

Di Cosimo S, La Verde N, Moretti A et al (2019) Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: results from the HOPE study. PLoS One 14:e0220644. https://doi.org/10.1371/journal.pone.0220644CrossRefPubMedPubMedCentral

23.

Razzaghi H, Troester MA, Gierach GL, Olshan AF, Yankaskas BC, Millikan RC (2012) Mammographic density and breast cancer risk in White and African American Women. Breast Cancer Res Treat 135:571–580. https://doi.org/10.1007/s10549-012-2185-3CrossRefPubMedPubMedCentral

24.

Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC (2017) Complete metabolic response on interim 18 F-fluorodeoxyglucose positron emission tomography/computed tomography to predict long-term survival in patients with breast cancer undergoing neoadjuvant chemotherapy. Oncologist 22:526–534. https://doi.org/10.1634/theoncologist.2016-0334CrossRefPubMedPubMedCentral

25.

Yoon HJ, Kim KH, Kim HY, Park H, Cho JY, Hong YJ, Park HW, Kim JH, Ahn Y, Jeong MH, Cho JG, Park JC (2019) Impacts of non-recovery of trastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer. Clin Res Cardiol 108:892–900. https://doi.org/10.1007/s00392-019-01417-xCrossRefPubMed

26.

Bonfill X, Roura P, Moreno C, Rivero E, Rué M (1997) Cancer mortality in the counties of Catalonia (1983-1989). Gac Sanit 11:74–82. https://doi.org/10.1016/s0213-9111(97)71279-2CrossRefPubMed

27.

Krishnaraj A, Yankaskas BC, Stearns SC (2006) Screening mammography after breast cancer treatment: patterns in community practice. Breast Cancer Res Treat 97:73–80CrossRefPubMed

28.

Landau-Ossondo M, Rabia N, Jos-Pelage J, Marquet LM, Isidore Y, Saint-Aimé C, Martin M, Irigaray P, Belpomme D, ARTAC international research group on pesticides (2009) Why pesticides could be a common cause of prostate and breast cancers in the French Caribbean Island, Martinique. An overview on key mechanisms of pesticide-induced cancer. Biomed Pharmacother 63:383–395CrossRefPubMed

29.

Boerma M (2018) Cardiovascular side effects of breast cancer therapy. In: Gender Differences in the pathogenesis and management of heart disease. Springer International Publishing, pp 303–316

30.

Imene A, Maurice AJ, Arij M et al (2015) Breast cancer association with CYP1A2 activity and gene polymorphisms--a preliminary case-control study in Tunisia. Asian Pac J Cancer Prev 16:3559–3563. https://doi.org/10.7314/apjcp.2015.16.8.3559CrossRefPubMed

31.

Radiotherapy effects on systolic myocardial function detected by strain rate imaging in a left-breast cancer patient - PubMed. https://pubmed.ncbi.nlm.nih.gov/17673445/. Accessed 1 Aug 2020

32.

Marinko T, Dolenc J, Bilban-Jakopin C (2014) Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer. Radiol Oncol 48:105–112CrossRefPubMedPubMedCentral

33.

Giordano G, Spagnuolo A, Olivieri N, Corbo C, Campagna A, Spagnoletti I, Pennacchio RM, Campidoglio S, Pancione M, Palladino L, Villari B, Febbraro A (2016) Cancer drug related cardiotoxicity during breast cancer treatment. Expert Opin Drug Saf 15:1063–1074CrossRefPubMed

34.

Thavendiranathan P, Amir E (2017) Left ventricular dysfunction with trastuzumab therapy: is primary prevention the best option? J Clin Oncol 35:820–825. https://doi.org/10.1200/JCO.2016.71.0038CrossRefPubMed

35.

Singla A, Kumar G, Bardia A (2012) Personalizing cardiovascular disease prevention among breast cancer survivors. Curr Opin Cardiol 27:1. https://doi.org/10.1097/HCO.0b013e3283570040CrossRef

36.

Nicolazzi MA, Carnicelli A, Fuorlo M et al (2018) Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci 22. https://doi.org/10.26355/EURREV_201804_14752

37.

Copeland-Halperin RS, Liu JE, Yu AF (2019) Cardiotoxicity of HER2-targeted therapies. Curr Opin Cardiol 34:451–458CrossRefPubMedPubMedCentral

38.

Foulkes SJ, Howden EJ, Bigaran A et al (2019) Persistent impairment in cardiopulmonary fitness after breast cancer chemotherapy. Med Sci Sports Exerc 51:1573–1581. https://doi.org/10.1249/MSS.0000000000001970CrossRefPubMed

39.

Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, Mabuchi K, Marks LB, Mettler FA, Pierce LJ, Trott KR, Yeh ETH, Shore RE (2010) Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76:656–665CrossRefPubMedPubMedCentral

40.

Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987–998. https://doi.org/10.1056/NEJMoa1209825CrossRefPubMed

41.

Van Den Bogaard VAB, Ta BDP, Van Der Schaaf A et al (2017) Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol 35:1171–1178. https://doi.org/10.1200/JCO.2016.69.8480CrossRefPubMedPubMedCentral

42.

Canney PA, Sanderson R, Deehan C, Wheldon T (2001) Variation in the probability of cardiac complications with radiation technique in early breast cancer. Br J Radiol 74:262–265. https://doi.org/10.1259/bjr.74.879.740262CrossRefPubMed

43.

Formenti SC, DeWyngaert JK, Jozsef G, Goldberg JD (2012) Prone vs supine positioning for breast cancer radiotherapy. JAMA 308:861–863CrossRefPubMed

44.

Lu HM, Cash E, Chen MH, Chin L, Manning WJ, Harris J, Bornstein B (2000) Reduction of cardiac volume in left-breast treatment fields by respiratory maneuvers: a CT study. Int J Radiat Oncol Biol Phys 47:895–904. https://doi.org/10.1016/S0360-3016(00)00512-5CrossRefPubMed

45.

Chhabra A, Langen K, Mehta MP (2016) An overview of modern proton therapy. Chinese. Clin Oncol 5:2. https://doi.org/10.21037/CCO.V0I0.10584CrossRef

46.

Dunet V, Schwitter J, Meuli R, Beigelman-Aubry C (2016) Incidental extracardiac findings on cardiac MR: systematic review and meta-analysis. J Magn Reson Imaging 43:929–939CrossRefPubMed

47.

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol - PubMed. https://pubmed.ncbi.nlm.nih.gov/26903532/. Accessed 6 Aug 2020

48.

Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI (2017) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35:870–877. https://doi.org/10.1200/JCO.2016.68.7830CrossRefPubMed

49.

Tuzovic M, Agarwal M, Thareja N, Yang EH (2019) Cardiac Toxicity of HER-2 Targeted Regimens

50.

Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P, International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis (2009) Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 53:1475–1487CrossRefPubMedPubMedCentral

51.

Ugander M, Bagi PS, Oki AJ, Chen B, Hsu LY, Aletras AH, Shah S, Greiser A, Kellman P, Arai AE (2012) Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. JACC Cardiovasc Imaging 5:596–603. https://doi.org/10.1016/j.jcmg.2012.01.016CrossRefPubMedPubMedCentral

52.

Motwani M, Kidambi A, Herzog BA, Uddin A, Greenwood JP, Plein S (2013) MR imaging of cardiac tumors and masses: a review of methods and clinical applications. Radiology 268:26–43CrossRefPubMed

53.

Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72:3158–3176CrossRefPubMed

54.

Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, Friedrich MG (2001) Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging - a pilot study. Am Heart J 141:1007–1013. https://doi.org/10.1067/mhj.2001.115436CrossRefPubMed

55.

Gräni C, Eichhorn C, Bière L, Murthy VL, Agarwal V, Kaneko K, Cuddy S, Aghayev A, Steigner M, Blankstein R, Jerosch-Herold M, Kwong RY (2017) Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol 70:1964–1976. https://doi.org/10.1016/j.jacc.2017.08.050CrossRefPubMedPubMedCentral

56.

Hulten E, Agarwal V, Cahill M, Cole G, Vita T, Parrish S, Bittencourt MS, Murthy VL, Kwong R, di Carli MF, Blankstein R (2016) Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-Analysis. Circ Cardiovasc Imaging 9. https://doi.org/10.1161/CIRCIMAGING.116.005001

57.

O’Hanlon R, Grasso A, Roughton M et al (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56:867–874. https://doi.org/10.1016/j.jacc.2010.05.010CrossRefPubMed

58.

Lunning MA, Kutty S, Rome ET, Li L, Padiyath A, Loberiza F, Bociek RG, Bierman PJ, Vose JM, Armitage JO, Porter TR (2015) Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy. Am J Clin Oncol 38:377–381. https://doi.org/10.1097/COC.0b013e31829e19beCrossRefPubMed

59.

Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick IDC, Singal PK, Krahn M, Grenier D, Jassal DS (2011) The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor iipositive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57:2263–2270. https://doi.org/10.1016/j.jacc.2010.11.063CrossRefPubMed

60.

Mackay B, Ewer MS, Carrasco CH, Benjamin RS (1994) Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol 18:203–211. https://doi.org/10.3109/01913129409016291CrossRefPubMed

61.

Bernaba BN, Chan JB, Lai CK, Fishbein MC (2010) Pathology of late-onset anthracycline cardiomyopathy. Cardiovasc Pathol 19:308–311. https://doi.org/10.1016/j.carpath.2009.07.004CrossRefPubMed

62.

Nayak KS, Nielsen JF, Bernstein MA, Markl M, D. Gatehouse P, M. Botnar R, Saloner D, Lorenz C, Wen H, S. Hu B, Epstein FH, N. Oshinski J, Raman SV (2015) Cardiovascular magnetic resonance phase contrast imaging. J Cardiovasc Magn Reson 17:71CrossRefPubMedPubMedCentral

63.

Chaosuwannakit N, D’Agostino R, Hamilton CA et al (2010) Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 28:166–172. https://doi.org/10.1200/JCO.2009.23.8527CrossRefPubMed

64.

Drafts BC, Twomley KM, D’Agostino R et al (2013) Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 6:877–885. https://doi.org/10.1016/j.jcmg.2012.11.017CrossRefPubMedPubMedCentral

65.

Chotenimitkhun R, Gregory Hundley W (2011) Pharmacological stress cardiovascular magnetic resonance. Postgrad Med 123:162–170. https://doi.org/10.3810/pgm.2011.05.2295CrossRefPubMedPubMedCentral

66.

Kramer CM, Barkhausen J, Flamm SD et al (2013) Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson 15:91CrossRefPubMedPubMedCentral

67.

Harries I, Liang K, Williams M, Berlot B, Biglino G, Lancellotti P, Plana JC, Bucciarelli-Ducci C (2020) Magnetic resonance imaging to detect cardiovascular effects of cancer therapy. JACC: CardioOncology 2:270–292. https://doi.org/10.1016/j.jaccao.2020.04.011CrossRefPubMedPubMedCentral

68.

Ong G, Brezden-Masley C, Dhir V, Deva DP, Chan KKW, Chow CM, Thavendiranathan D, Haq R, Barfett JJ, Petrella TM, Connelly KA, Yan AT (2018) Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy. Int J Cardiol 261:228–233. https://doi.org/10.1016/j.ijcard.2018.03.041CrossRefPubMed

69.

Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhães A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 27:911–939. https://doi.org/10.1016/j.echo.2014.07.012CrossRefPubMed

70.

Poterucha JT, Kutty S, Lindquist RK, Li L, Eidem BW (2012) Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction. J Am Soc Echocardiogr 25:733–740. https://doi.org/10.1016/j.echo.2012.04.007CrossRefPubMed

71.

Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH (2013) Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 26:493–498. https://doi.org/10.1016/j.echo.2013.02.008CrossRefPubMed

72.

Jordan JH, Sukpraphrute B, Meléndez GC, Jolly MP, D’Agostino RB Jr, Hundley WG (2017) Early myocardial strain changes during potentially cardiotoxic chemotherapy may occur as a result of reductions in left ventricular end-diastolic volume: the need to interpret left ventricular strain with volumes. Circulation 135:2575–2577CrossRefPubMedPubMedCentral

73.

Thavendiranathan P, Amir E, Bedard P, Crean A, Paul N, Nguyen ET, Wintersperger BJ (2014) Regional myocardial edema detected by T2 mapping is a feature of cardiotoxicity in breast cancer patients receiving sequential therapy with anthracyclines and trastuzumab. J Cardiovasc Magn Reson 16:P273. https://doi.org/10.1186/1532-429x-16-s1-p273CrossRefPubMedCentral

74.

Cardiovascular toxicity of the first line cancer chemotherapeutic agents: doxorubicin, cyclophosphamide, streptozotocin and bevacizumab - PubMed. https://pubmed.ncbi.nlm.nih.gov/17159809/. Accessed 1 Aug 2020

75.

Salerno M, Sharif B, Arheden H, Kumar A, Axel L, Li D, Neubauer S (2017) Recent advances in cardiovascular magnetic resonance. Circ Cardiovasc Imaging 10. https://doi.org/10.1161/CIRCIMAGING.116.003951

76.

Taylor AJ, Salerno M, Dharmakumar R, Jerosch-Herold M (2016) T1 mapping basic techniques and clinical applications. JACC Cardiovasc Imaging 9:67–81CrossRefPubMed

77.

Bönner F, Spieker M, Haberkorn S et al (2016) Myocardial T2 mapping increases noninvasive diagnostic accuracy for biopsy-proven myocarditis. JACC Cardiovasc Imaging 9:1467–1469CrossRefPubMed

78.

Abdel-Aty H, Zagrosek A, Schulz-Menger J, Taylor AJ, Messroghli D, Kumar A, Gross M, Dietz R, Friedrich MG (2004) Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation 109:2411–2416. https://doi.org/10.1161/01.CIR.0000127428.10985.C6CrossRefPubMed

79.

Haaf P, Garg P, Messroghli DR et al (2016) Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson 18

80.

Neilan TG, Coelho-Filho OR, Shah RV, Feng JH, Pena-Herrera D, Mandry D, Pierre-Mongeon F, Heydari B, Francis SA, Moslehi J, Kwong RY, Jerosch-Herold M (2013) Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol 111:717–722. https://doi.org/10.1016/j.amjcard.2012.11.022CrossRefPubMed

81.

An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity - PubMed. https://pubmed.ncbi.nlm.nih.gov/24675088/. Accessed 6 Aug 2020

82.

Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, Daniel Donovan F, Metzger ML, Arevalo A, Durand JB, Joshi V, Hudson MM, Robison LL, Flamm SD (2012) Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 30:2876–2884. https://doi.org/10.1200/JCO.2011.40.3584CrossRefPubMedPubMedCentral

83.

Lawley C, Wainwright C, Segelov E et al (2012) Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer. Asia Pac J Clin Oncol 8:95–100. https://doi.org/10.1111/j.1743-7563.2011.01462.xCrossRefPubMed

84.

Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T, Summers AR, Singal PK, Barac I, Kirkpatrick ID, Jassal DS (2010) Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 28:3429–3436. https://doi.org/10.1200/JCO.2009.26.7294CrossRefPubMed

85.

Dhir V, Yan AT, Nisenbaum R, Sloninko J, Connelly KA, Barfett J, Haq R, Kirpalani A, Chan KKW, Petrella TM, Brezden-Masley C (2019) Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study. Int J Cardiovasc Imaging 35:2085–2093. https://doi.org/10.1007/s10554-019-01648-zCrossRefPubMed

86.

Nakano S, Takahashi M, Kimura F, Senoo T, Saeki T, Ueda S, Tanno J, Senbonmatsu T, Kasai T, Nishimura S (2016) Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: a pilot study to evaluate the feasibility of the method. Cardiol J 23:270–280. https://doi.org/10.5603/CJ.a2016.0023CrossRefPubMed

87.

Song L, Brezden-Masley C, Ramanan V, Ghugre N, Barfett JJ, Chan KKW, Haq R, Petrella T, Dhir V, Jimenez-Juan L, Chacko BR, Kotha V, Connelly KA, Yan AT (2019) Serial measurements of left ventricular systolic and diastolic function by cardiac magnetic resonance imaging in patients with early stage breast cancer on trastuzumab. Am J Cardiol 123:1173–1179. https://doi.org/10.1016/j.amjcard.2018.12.046CrossRefPubMed

88.

CMR in the Evaluation of LV Diastolic Dysfunction - American College of Cardiology. https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2020/01/10/11/30/cmr-in-the-evaluation-of-diastolic-dysfunction. Accessed 6 Aug 2020

89.

Saiki H, Petersen IA, Scott CG, Bailey KR, Dunlay SM, Finley RR, Ruddy KJ, Yan E, Redfield MM (2017) Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation 135:1388–1396. https://doi.org/10.1161/CIRCULATIONAHA.116.025434CrossRefPubMedPubMedCentral

90.

Ben-Horin S, Banke I, Guetta V, Livneh A (2006) Large symptomatic pericardial effusion as the presentation of unrecognized cancer: a study in 173 consecutive patients undergoing pericardiocentesis. Medicine 85:49–53. https://doi.org/10.1097/01.md.0000199556.69588.8eCrossRefPubMed

91.

Barthur A, Brezden-Masley C, Connelly KA, Dhir V, Chan KKW, Haq R, Kirpalani A, Barfett JJ, Jimenez-Juan L, Karur GR, Deva DP, Yan AT (2017) Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. J Cardiovasc Magn Reson 19. https://doi.org/10.1186/s12968-017-0356-4

92.

Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS (2008) Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson:10. https://doi.org/10.1186/1532-429X-10-5

93.

Ferreira de Souza T, Quinaglia AC, Silva T, Osorio Costa F et al (2018) Anthracycline therapy is associated with cardiomyocyte atrophy and preclinical manifestations of heart disease. JACC Cardiovasc Imaging 11:1045–1055. https://doi.org/10.1016/j.jcmg.2018.05.012CrossRefPubMed

94.

Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial - PubMed. https://pubmed.ncbi.nlm.nih.gov/29106497/. Accessed 1 Aug 2020

95.

Galán-Arriola C, Lobo M, Vílchez-Tschischke JP, López GJ, de Molina-Iracheta A, Pérez-Martínez C, Agüero J, Fernández-Jiménez R, Martín-García A, Oliver E, Villena-Gutierrez R, Pizarro G, Sánchez PL, Fuster V, Sánchez-González J, Ibanez B (2019) Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 73:779–791. https://doi.org/10.1016/j.jacc.2018.11.046CrossRefPubMed

96.

Altaha MA, Nolan M, Marwick TH, Somerset E, Houbois C, Amir E, Yip P, Connelly KA, Michalowska M, Sussman MS, Wintersperger BJ, Thavendiranathan P (2020) Can quantitative cmr tissue characterization adequately identify cardiotoxicity during chemotherapy?: impact of temporal and observer variability. JACC Cardiovasc Imaging 13:951–962. https://doi.org/10.1016/j.jcmg.2019.10.016CrossRefPubMed

97.

Gong IY, Ong G, Brezden-Masley C, Dhir V, Deva DP, Chan KKW, Graham JJ, Chow CM, Thavendiranathan P, Dai D, Ng MY, Barfett JJ, Connelly KA, Yan AT (2019) Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study. Int J Cardiovasc Imaging 35:653–662. https://doi.org/10.1007/s10554-018-1482-2CrossRefPubMed

98.

Jasaityte R, Claus P, Teske AJ, Herbots L, Verheyden B, Jurcut R, Rademakers F, D'hooge J (2013) The slope of the segmental stretch-strain relationship as a noninvasive index of LV inotropy. JACC Cardiovasc Imaging 6:419–428. https://doi.org/10.1016/j.jcmg.2012.10.022CrossRefPubMed

99.

Jordan JH, Vasu S, Morgan TM et al (2016) Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging 9. https://doi.org/10.1161/CIRCIMAGING.115.004325

100.

Kimball A, Patil S, Koczwara B, Raman KS, Perry R, Grover S, Selvanayagam J (2018) Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients. Int J Cardiol 261:159–161. https://doi.org/10.1016/j.ijcard.2018.03.025CrossRefPubMed

101.

Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH (2017) Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol 70:2552–2565CrossRefPubMedPubMedCentral

102.

Dogan SE, Mizrak D, Alkan A, Demirkazik A (2017) Docetaxel-induced pericardial effusion. J Oncol Pharm Pract 23:389–391. https://doi.org/10.1177/1078155216643859CrossRefPubMed

103.

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC. https://pubmed.ncbi.nlm.nih.gov/27567406/. Accessed 6 Aug 2020

104.

Ning MS, Tang L, Gomez DR, Xu T, Luo Y, Huo J, Mouhayar E, Liao Z (2017) Incidence and predictors of pericardial effusion after chemoradiation therapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 99:70–79. https://doi.org/10.1016/j.ijrobp.2017.05.022CrossRefPubMedPubMedCentral

105.

Pericardial disease associated with malignancy - UpToDate. https://www.uptodate.com/contents/pericardial-disease-associated-with-malignancy. Accessed 15 Aug 2020

106.

Hoey ETD, Gulati GS, Ganeshan A, Watkin RW, Simpson H, Sharma S (2011) Cardiovascular MRI for assessment of infectious and inflammatory conditions of the heart. Am J Roentgenol 197:103–112CrossRef

107.

Bogaert J, Francone M (2009) Cardiovascular magnetic resonance in pericardial diseases. J Cardiovasc Magn Reson 11

108.

Richardson P, McKenna RW, Bristow M et al (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 93:841–842CrossRefPubMed

109.

Gujral DM, Lloyd G, Bhattacharyya S (2016) Radiation-induced valvular heart disease. Heart 102:269–276CrossRefPubMed

110.

Wethal T, Lund MB, Edvardsen T, Fosså SD, Pripp AH, Holte H, Kjekshus J, Fosså A (2009) Valvular dysfunction and left ventricular changes in Hodgkin’s lymphoma survivors. A longitudinal study. Br J Cancer 101:575–581. https://doi.org/10.1038/sj.bjc.6605191CrossRefPubMedPubMedCentral

111.

Amin HZ, Amin LZ, Pradipta A (2020) Takotsubo cardiomyopathy: a brief review. J Med Life 13:3–7PubMedPubMedCentral

112.

Desai A, Noor A, Joshi S, Kim AS (2019) Takotsubo cardiomyopathy in cancer patients. https://doi.org/10.1186/s40959-019-0042-9

113.

Molteni LP, Rampinelli I, Cergnul M, Scaglietti U, Paino AM, Noonan DM, Bucci EO, Gottardi O, Albini A (2010) Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment. Breast J 16:S45–S48CrossRefPubMed

114.

Qasem A, Bin Abdulhak AA, Aly A, Moormeier J (2016) Capecitabine-tnduced Takotsubo cardiomyopathy. Am J Ther 23:e1188–e1192. https://doi.org/10.1097/MJT.0000000000000134CrossRefPubMed

115.

Khanji M, Nolan S, Gwynne S, Pudney D, Ionescu A (2013) Tako-Tsubo syndrome after trastuzumab - an unusual complication of chemotherapy for breast cancer. Clin Oncol 25:329CrossRef

116.

Balanescu DV, Liu VY, Donisan T et al (2018) P1253Clinical features and outcomes of patients with chemotherapy-induced Takotsubo stress cardiomyopathy. Eur Heart J 39. https://doi.org/10.1093/eurheartj/ehy565.p1253

117.

Cammann VL, Sarcon A, Ding KJ et al (2019) Clinical features and outcomes of patients with malignancy and Takotsubo syndrome: observations from the International Takotsubo Registry. J Am Heart Assoc 8. https://doi.org/10.1161/JAHA.118.010881

118.

Bratis K (2017) Cardiac magnetic resonance in Takotsubo syndrome. Eur Cardiol Rev 12:58–62CrossRef

119.

Smith REA, Dobbs HJ, Martin JF (1993) Radiotherapy, left-sided breast cancer, and ischaemic heart disease. Br Heart J 69:483–484CrossRefPubMedPubMedCentral

120.

Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, Piña IL, Volgman AS (2018) Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation 137:e30–e66. https://doi.org/10.1161/CIR.0000000000000556CrossRefPubMedPubMedCentral

121.

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Socie. https://pubmed.ncbi.nlm.nih.gov/28886621/. Accessed 6 Aug 2020

122.

Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, Hert SD, Ford I, Gonzalez-Juanatey JR, Gorenek B, Heyndrickx GR, Hoeft A, Huber K, Iung B, Kjeldsen KP, Longrois D, Lüscher TF, Pierard L, Pocock S, Price S, Roffi M, Sirnes PA, Sousa-Uva M, Voudris V, Funck-Brentano C, Authors/Task Force Members (2014) 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 35:2383–2431. https://doi.org/10.1093/eurheartj/ehu282CrossRefPubMed

123.

Hooning MJ, Botma A, Aleman BMP, Baaijens MHA, Bartelink H, Klijn JGM, Taylor CW, van Leeuwen FE (2007) Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99:365–375. https://doi.org/10.1093/jnci/djk064CrossRefPubMed

124.

Stewart MH, Jahangir E, Polin NM (2017) Valvular heart disease in cancer patients: etiology, diagnosis, and management. Curr Treat Options Cardiovasc Med 19

125.

Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I (2003) Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 42:743–749. https://doi.org/10.1016/S0735-1097(03)00759-9CrossRefPubMed

126.

Veeragandham RS, Goldin MD (1998) Surgical management of radiation-induced heart disease. Ann Thorac Surg 65:1014–1019. https://doi.org/10.1016/s0003-4975(98)00082-4CrossRefPubMed

127.

Sato A, Yoshihisa A, Miyata-Tatsumi M et al (2019) Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer. Mol Clin Oncol 10:37–42. https://doi.org/10.3892/mco.2018.1764CrossRefPubMed

128.

Søndergaard L, Hildebrandt P, Lindvig K, Thomsen C, Stȧahlberg F, Kassis E, Henriksen O (1993) Valve area and cardiac output in aortic stenosis: quantification by magnetic resonance velocity mapping. Am Heart J 126:1156–1164. https://doi.org/10.1016/0002-8703(93)90669-ZCrossRefPubMed

129.

von Hoff DD, Layard MW, Basa P, Davis HL Jr, von Hoff A, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717. https://doi.org/10.7326/0003-4819-91-5-710CrossRef

130.

Russo G, Cioffi G, Gori S, Tuccia F, Boccardi L, Khoury G, Lestuzzi C, Maurea N, Oliva S, Faggiano P, Tarantini L (2014) Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. J Cardiovasc Med 15:141–146. https://doi.org/10.2459/JCM.0b013e328365afb5CrossRef

131.

Han H, Guo W, Shi W, Yu Y, Zhang Y, Ye X, He J (2017) Hypertension and breast cancer risk: a systematic review and meta-analysis. Sci Rep 7. https://doi.org/10.1038/srep44877

132.

Cameron AC, Touyz RM, Lang NN (2016) Vascular complications of cancer chemotherapy. Can J Cardiol 32:852–862CrossRefPubMed

133.

Burger A, Löffler H, Bamberg M, Rodemann HP (1998) Molecular and cellular basis of radiation fibrosis. In: International Journal of Radiation Biology. Taylor & Francis, pp 401–408

134.

Jurado JA, Bashir R, Burket MW (2008) Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv 72:563–568. https://doi.org/10.1002/ccd.21681CrossRefPubMed

135.

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981–1988. https://doi.org/10.1161/CIRCULATIONAHA.114.013777CrossRefPubMed

136.

Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel el Jr (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. J Am Med Assoc 291:2441–2447. https://doi.org/10.1001/jama.291.20.2441CrossRef

Titel: The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review
verfasst von: Fatemeh Jafari
Afsane Maddah Safaei
Leila Hosseini
Sanaz Asadian
Tara Molanaie Kamangar
Fatemeh Zadehbagheri
Nahid Rezaeian
Publikationsdatum: 07.10.2020
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 3/2021
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-020-10028-y

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review

Abstract

Neu im Fachgebiet Kardiologie

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Darf man die Behandlung eines Neonazis ablehnen?

Update Kardiologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Efficacy of adaptive servo-ventilation and continuous positive airway pressure treatment in chronic heart failure with sleep-disordered breathing: a systematic review and meta-analysis

The utility of cardiovascular imaging in heart failure with preserved ejection fraction: diagnosis, biological classification and risk stratification

Exercise rehabilitation in cardiac resynchronization: systematic review and a meta-analysis

Impact of atrial fibrillation on the outcomes of transcatheter mitral valve repair using MitraClip: a systematic review and meta-analysis

Ultrafiltration is better than diuretic therapy for volume-overloaded acute heart failure patients: a meta-analysis

Vitamin C: historical perspectives and heart failure

Neu im Fachgebiet Kardiologie

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Darf man die Behandlung eines Neonazis ablehnen?

Update Kardiologie